FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602413312> ?p ?o ?g. }

• W2602413312 endingPage "e17025" @default.
• W2602413312 startingPage "e17025" @default.
• W2602413312 abstract "e17025 Background: Histone deacetylase (HDAC) inhibitors suppress tumor cell proliferation in medullary thyroid cancer (MTC) and differentiated thyroid cancer (DTC) in vivo. We conducted a multicenter single arm phase II trial of panobinostat, a potent inhibitor of Class I, II, and IV HDAC enzymes, in MTC and radioactive iodine (RAI)-refractory DTC. Methods: We enrolled 13 patients (pts) with progressive metastatic MTC or RAI-refractory DTC. Panobinostat was given at 20 mg orally TIW until disease progression or intolerable toxicities. The primary objective was anti-tumor response rate; secondary objectives included overall survival (OS), progression-free survival (PFS), tolerability, and changes in serum thyroglobulin (Tg) concentration. Results: Mean age was 61±13 yrs; 7 pts were female. 11 pts had DTC; 2 had MTC. Median study follow-up was 11.8 months (mos). 9 pts required dose holds/reductions due to thrombocytopenia (n=7), hypocalcemia (n=3), neutropenia (n=2), diarrhea (n=1), bone pain (n=1), or asthenia (n=1). Due to protocol specified rules, 2 pts were withdrawn from therapy with thrombocytopenia or neutropenia, both asymptomatic. Of the 3 pts with ≥ grade 3 thrombocytopenia, 2 had no bleeding. The third pt continued to bleed from her chronically erosive tumor without exacerbation. Median duration of treatment was 2.1 mos (range, 0.8-11.8). Stable disease (SD) was seen in 7 pts, with a median duration of 5.8 mos (range,1.8-13.8). All 7 SD pts are currently alive, including 2 with SD 4.9 mo and 11.8 mo on treatment. Progressive disease (PD) occurred, and was the cause of death, in 6 pts.No anti-tumor responses were observed. Median PFS for the 13 pts was 3.6 mos (95% CI, 1.8-5.8), with 2 pts having a PFS longer than 6 mos.Median OS for the 13 pts was 18.4 mos (95% CI, 5.8-not estimable). 5 of 11 pts had reductions of their serum Tg on study; however, changes in serial Tg values did not distinguish PD from SD pts. Conclusions: 20 mg TIW was not tolerated by most pts. However, dose modified treatment yielded SD in half of our previously progressing pts. This promising disease stabilization warrants further evaluation, possibly in combination with a VEGFR TKI. Clinical trial information: NCT01013597." @default.
• W2602413312 created "2017-04-07" @default.
• W2602413312 creator A5002970130 @default.
• W2602413312 creator A5006951973 @default.
• W2602413312 creator A5007840845 @default.
• W2602413312 creator A5013271402 @default.
• W2602413312 creator A5019192539 @default.
• W2602413312 creator A5021263646 @default.
• W2602413312 creator A5040571934 @default.
• W2602413312 creator A5048848751 @default.
• W2602413312 creator A5054134336 @default.
• W2602413312 creator A5064919306 @default.
• W2602413312 creator A5088700876 @default.
• W2602413312 date "2013-05-20" @default.
• W2602413312 modified "2023-09-26" @default.
• W2602413312 title "Panobinostat, a novel histone deacetylase inhibitor, in advanced medullary and iodine-refractory differentiated thyroid cancer: A Wisconsin Oncology Network trial." @default.
• W2602413312 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e17025" @default.
• W2602413312 hasPublicationYear "2013" @default.
• W2602413312 type Work @default.
• W2602413312 sameAs 2602413312 @default.
• W2602413312 citedByCount "5" @default.
• W2602413312 countsByYear W26024133122013 @default.
• W2602413312 countsByYear W26024133122014 @default.
• W2602413312 countsByYear W26024133122018 @default.
• W2602413312 countsByYear W26024133122020 @default.
• W2602413312 countsByYear W26024133122022 @default.
• W2602413312 crossrefType "journal-article" @default.
• W2602413312 hasAuthorship W2602413312A5002970130 @default.
• W2602413312 hasAuthorship W2602413312A5006951973 @default.
• W2602413312 hasAuthorship W2602413312A5007840845 @default.
• W2602413312 hasAuthorship W2602413312A5013271402 @default.
• W2602413312 hasAuthorship W2602413312A5019192539 @default.
• W2602413312 hasAuthorship W2602413312A5021263646 @default.
• W2602413312 hasAuthorship W2602413312A5040571934 @default.
• W2602413312 hasAuthorship W2602413312A5048848751 @default.
• W2602413312 hasAuthorship W2602413312A5054134336 @default.
• W2602413312 hasAuthorship W2602413312A5064919306 @default.
• W2602413312 hasAuthorship W2602413312A5088700876 @default.
• W2602413312 hasConcept C104317684 @default.
• W2602413312 hasConcept C121608353 @default.
• W2602413312 hasConcept C126322002 @default.
• W2602413312 hasConcept C141071460 @default.
• W2602413312 hasConcept C143998085 @default.
• W2602413312 hasConcept C185592680 @default.
• W2602413312 hasConcept C197934379 @default.
• W2602413312 hasConcept C2776694085 @default.
• W2602413312 hasConcept C2777063308 @default.
• W2602413312 hasConcept C2778305200 @default.
• W2602413312 hasConcept C2778375690 @default.
• W2602413312 hasConcept C2778850193 @default.
• W2602413312 hasConcept C2779761222 @default.
• W2602413312 hasConcept C2780225316 @default.
• W2602413312 hasConcept C2780256643 @default.
• W2602413312 hasConcept C55493867 @default.
• W2602413312 hasConcept C64927066 @default.
• W2602413312 hasConcept C71924100 @default.
• W2602413312 hasConcept C90924648 @default.
• W2602413312 hasConceptScore W2602413312C104317684 @default.
• W2602413312 hasConceptScore W2602413312C121608353 @default.
• W2602413312 hasConceptScore W2602413312C126322002 @default.
• W2602413312 hasConceptScore W2602413312C141071460 @default.
• W2602413312 hasConceptScore W2602413312C143998085 @default.
• W2602413312 hasConceptScore W2602413312C185592680 @default.
• W2602413312 hasConceptScore W2602413312C197934379 @default.
• W2602413312 hasConceptScore W2602413312C2776694085 @default.
• W2602413312 hasConceptScore W2602413312C2777063308 @default.
• W2602413312 hasConceptScore W2602413312C2778305200 @default.
• W2602413312 hasConceptScore W2602413312C2778375690 @default.
• W2602413312 hasConceptScore W2602413312C2778850193 @default.
• W2602413312 hasConceptScore W2602413312C2779761222 @default.
• W2602413312 hasConceptScore W2602413312C2780225316 @default.
• W2602413312 hasConceptScore W2602413312C2780256643 @default.
• W2602413312 hasConceptScore W2602413312C55493867 @default.
• W2602413312 hasConceptScore W2602413312C64927066 @default.
• W2602413312 hasConceptScore W2602413312C71924100 @default.
• W2602413312 hasConceptScore W2602413312C90924648 @default.
• W2602413312 hasIssue "15_suppl" @default.
• W2602413312 hasLocation W26024133121 @default.
• W2602413312 hasOpenAccess W2602413312 @default.
• W2602413312 hasPrimaryLocation W26024133121 @default.
• W2602413312 hasRelatedWork W2014862321 @default.
• W2602413312 hasRelatedWork W2066251854 @default.
• W2602413312 hasRelatedWork W2074502555 @default.
• W2602413312 hasRelatedWork W2411510431 @default.
• W2602413312 hasRelatedWork W2514569171 @default.
• W2602413312 hasRelatedWork W2596696390 @default.
• W2602413312 hasRelatedWork W2597622839 @default.
• W2602413312 hasRelatedWork W2620029856 @default.
• W2602413312 hasRelatedWork W2942652260 @default.
• W2602413312 hasRelatedWork W4307641348 @default.
• W2602413312 hasVolume "31" @default.
• W2602413312 isParatext "false" @default.
• W2602413312 isRetracted "false" @default.
• W2602413312 magId "2602413312" @default.
• W2602413312 workType "article" @default.